Inspire Medical Systems (NYSE:INSP) Price Target Raised to $65.00

Inspire Medical Systems (NYSE:INSP) had its target price upped by JPMorgan Chase & Co. from $60.00 to $65.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

INSP has been the topic of a number of other reports. Evercore set a $54.00 target price on Inspire Medical Systems in a research report on Tuesday, August 4th. Piper Sandler lifted their price target on Inspire Medical Systems from $60.00 to $70.00 and gave the company a “neutral” rating in a research note on Tuesday. UBS Group assumed coverage on Inspire Medical Systems in a report on Tuesday, July 28th. They issued a “sell” rating and a $39.00 price target for the company. Truist Financial reiterated a “hold” rating and set a $76.00 price target (down from $78.00) on shares of Inspire Medical Systems in a research report on Tuesday. Finally, Wells Fargo & Company increased their price target on Inspire Medical Systems from $56.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $71.24.

Inspire Medical Systems Stock Performance

INSP stock opened at $66.45 on Tuesday. The firm has a market cap of $1.93 billion, a PE ratio of 32.81, a P/E/G ratio of 4.87 and a beta of 0.67. The firm’s fifty day moving average is $68.89 and its 200 day moving average is $58.38. Inspire Medical Systems has a one year low of $38.91 and a one year high of $147.03.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $206.69 million during the quarter, compared to analysts’ expectations of $204.31 million. Inspire Medical Systems had a net margin of 11.43% and a return on equity of 7.32%. The firm’s revenue for the quarter was down 7.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.38 earnings per share. Research analysts predict that Inspire Medical Systems will post 1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inspire Medical Systems

A number of large investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its position in shares of Inspire Medical Systems by 1,115.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after purchasing an additional 580 shares during the last quarter. Sterling Capital Management LLC lifted its stake in Inspire Medical Systems by 450.6% in the 3rd quarter. Sterling Capital Management LLC now owns 914 shares of the company’s stock valued at $63,000 after buying an additional 748 shares in the last quarter. Versant Capital Management Inc lifted its stake in Inspire Medical Systems by 379.0% in the 2nd quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock valued at $43,000 after buying an additional 758 shares in the last quarter. Pinnacle Wealth Planning Services Inc. boosted its holdings in Inspire Medical Systems by 19.8% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,172 shares of the company’s stock worth $81,000 after buying an additional 194 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Inspire Medical Systems by 68.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,200 shares of the company’s stock worth $83,000 after buying an additional 488 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Piper Sandler and Robert W. Baird were reported as expecting the stock to appreciate, offering some support amid weaker sentiment. Piper Sandler forecast Baird forecast
• Positive Sentiment: A bullish analysis argued Inspire’s competitive advantage held up under a severe stress test, suggesting the company may retain durable long-term strengths. Bullish competitive-position analysis
• Neutral Sentiment: Q3 results were mixed: revenue of $206.7 million modestly exceeded estimates, while falling 7.9% year over year; reported EPS of $0.14 beat the $0.09 consensus but was below $0.38 a year earlier. This points to continued growth and profitability concerns despite the estimate beats. Q3 earnings call summary
• Negative Sentiment: Inspire narrowed its full-year 2026 earnings guidance, a signal investors may interpret as reduced visibility or a weaker outlook. 2026 guidance update
• Negative Sentiment: Barclays maintained its Sell rating, and coverage linked an analyst downgrade to a sharp decline in the shares. This adds pressure alongside questions about cash flow and whether the stock has fallen enough. Barclays rating Cash-flow valuation discussion

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.